Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CRWD
5. CHKP
6. ON
7. HNGE
8. INSP
9. SPY
10. MRVL

Go back to Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance

Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at BofA Securities

May 10, 2024 5:24 AM EDT

BofA Securities analyst Tazeen Ahmad lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $22.00 (from $26.00) while maintaining a Neutral rating.

The analyst comments "ACAD reported 1Q24 Daybue revenues of $75.9mn slightly missing their 1Q guidance of $76-82mn. Mgmt attributed the 1Q... More